Gammagard™ Misses Endpoints in Phase 3 Trial
Topline data yesterday showed that intravenous immunoglobulin (IVIG) therapy, known as Gammagard™, failed to meet primary endpoints of slowing cognitive and functional decline...
6397 RESULTS
Sort By:
Topline data yesterday showed that intravenous immunoglobulin (IVIG) therapy, known as Gammagard™, failed to meet primary endpoints of slowing cognitive and functional decline...
It has become a complaint heard all too often—much academic research cannot be reproduced...
Scientists report that endocytosis whisks α-secretase away from the cell membrane in a process that seems regulated by neuronal activity...
As β-secretase inhibitors head into Alzheimer’s disease trials, researchers are paying close attention to what else BACE1 does besides snip amyloid-β from APP...
At a San Francisco conference addressing Alzheimer’s and related disorders, the agenda featured a diverse mix of topics—occasionally even from the same lab...
Today, the MetLife Foundation honored Yueming Li and Lennart Mucke with its 2013 Awards for Medical Research in Alzheimer’s Disease...
Two new papers this month shore up the connection between cell waste disposal and function of neurons...
Alzheimer's disease researchers expressed sadness this week at the sudden death of Larry Sparks...
Skin cancer, a common and typically curable malignancy, may carry a fringe benefit—protection from Alzheimer’s disease...
Scientists report the first successful generation of human embryonic stem cells via somatic cell nuclear transfer...
Scientists report that reducing hypertension may ward off amyloid pathology in people who have the ε4 version of the ApoE gene...
Results of a two-year clinical trial suggest that a mixture of B vitamins slows atrophy up to sevenfold in areas of the brain that are vulnerable to degeneration in AD...
In a study, scientists included rare types of parkinsonism and categorized them by their underlying proteinopathy...
Twenty years after the identification of the mutant gene that causes Huntington’s disease, scientists are ready to take therapies that target it into human trials...
As attention shifts toward free-floating Aβ oligomers as the prime molecular culprits in AD, there is still plenty of confusion over the role of fibrillar amyloid...
No filters selected